Anaplastic nasopharyngeal carcinoma (NPC) cells invariably harbor the Epstein-Barr virus (EBV) genome, an association that is unique among human virus-associated cancers. Although EBV is able to replicate in epithelial cells, results with expression of the EBV receptor (complement receptor type 2 [CR2]; also called CD21) in normal and malignant epithelial cells are conflicting. We grew five different EBV-associated NPC tumors in nude mice, and by using a sensitive transcriptional assay, we detected a very weak transcription signal of the EBV receptor CR2 gene in these cells. This suggests that low levels of EBV receptor may be expressed by malignant epithelial nasopharyngeal cells. The gene coding for Blast2/CD23, a B-cell activation molecule induced by EBV, was transcribed in three of the transplanted NPC tumors. The soluble form of the Blast2/CD23 protein was also detected in medium taken from short-term cultures of the same NPC cell lines. In contrast to the lymphoid system, in which Blast2/CD23 expression is associated with EBV nuclear antigen (EBNA2) expression, no EBNA2 protein could be detected in these NPC epithelial cells. Our study represents the first demonstration of Blast2/CD23 expression in epithelial cells. As the soluble form of the Blast2/CD23 protein possesses growth factor activity associated with EBV-induced B-cell immortalization, these results suggest a possible role for this molecule in the pathogenesis of NPC.
Nasopharyngeal carcinoma (NPC) is seen worldwide, but it occurs with a very high incidence in Southern China, where it represents the most common tumor in males (for review, see reference 9) . Two striking features of this cancer are the constant detection of Epstein-Barr virus (EBV) genome in NPC cells (8, 39) and the regular infiltration of the tumor by nonmalignant lymphocytes (16) .
EBV is a B-lymphotropic virus, and therefore the invariable presence of EBV DNA in malignant epithelial NPC cells is puzzling. The B-cell receptor for EBV is a cellular glycoprotein of 145 kilodaltons (kDa), identical to the receptor for the C3d fraction of complement, complement receptor type 2 (CR2; also called CD21) (11, 12) . CR2 is mainly expressed on B lymphocytes, although it is also present on follicular dendritic cells (22) . A molecule sharing one epitope with the EBV receptor CR2 and recognized by three anti-CR2 monoclonal antibodies is also expressed on normal stratified pharyngeal and ectocervical epithelia in a cell differentiation-dependent manner (26, 34, 36) .
No clear-cut results have been obtained concerning the expression of EBV receptor CR2 on NPC cells (13, 14) . Studies have been hampered mainly by the lack of a long-term culture method for NPC cells and because NPC tumors are heavily infiltrated with lymphoid cells. Despite the presence of the EBV genome in NPC cells, its role in the malignant process is unknown. EBV is known to be a potent "immortalizing agent" capable of transforming human B lymphocytes to a state of continuous proliferation in vitro. A set of leukocyte markers are known to be up regulated in EBV-infected B cells, and these are probably involved in the immortalization process (6) . These include not only the EBV receptor CR2, but also the 45-kDa leukocyte antigen Blast2/CD23, which is turned on in B cells following EBV infection (29, 30) . Blast2/CD23 seems to be a pivotal molecule in EBV-induced cell proliferation since it is a labile protein transiently expressed on the cell surface and then processed and shed as a soluble form which possesses B-cell growth factor activity (28) . As for the study of EBV receptor CR2, the analysis of Blast2/CD23 expression in NPC has been difficult due to lack of an efficient in vitro NPC culture system. Through the transplantation of NPC tumors into nude mice, it was possible to obtain abundant homogeneous material without lymphoid contamination. We of human origin, total cellular DNA was extracted from the five NPC tumors passaged in nude mice, from human cells, and from mice tissues. Each DNA (5 p.g) was analyzed by dot blotting and hybridized with the humanspecific Alui and with the murine-specific Bi probes. We were able to confirm that transplanted NPC tumors were composed mainly of human malignant materials (data not shown). The mouse cell infiltrates quantified with the Bi probe, while constant between the different NPC tumors, were nevertheless higher than the 1% of the cell population described previously (4) . EBV nuclear antigen (EBNA) was detected by anticomplement immunofluorescence in all five tumor lines, but antigens of the replicative cycle, such as VCA, EA, and MA antigens, were not detectable (4) .
RNA isolation and Northern (RNA) blot analysis. Total cellular RNA was prepared by the guanidium isothiocyanate-cesium chloride centrifugation method (7) . From [2] ) per ml in 0.1 M carbonate buffer (pH 9.6) at 4°C overnight. The wells were then washed five times with phosphate-buffered saline (PBS) containing 0.05% Tween 20 (Tween-PBS; washing was always performed with this buffer) and coated with PBS containing 2% bovine serum albumin (BSA) for at least 4 h at room temperature. After five washings, 100-pl samples were added to the wells and the plates were incubated at 4°C overnight. Plates were then washed five times, and 50 p.l of alkaline phosphatase-coupled anti-CD23 monoclonal antibody H107 (kindly provided by J. Yodoi [21] ), diluted at 2 p.g/ml with 2% BSA-PBS, was added to each well. The plates were then incubated overnight at 4°C, washed five times, and supplemented with 100 p.l of p-nitrophenyl phosphate (1 mg/ml) (Sigma) diluted with 9.7% diethanolamine, 3 mM (ii) Anti-EBNAl rabbit serum. The HindIlI I1 fragment from the EBV M-ABA genome corresponding to the EBNA1 open reading frame was cloned in the pEX vector (27) and then used to transform E. coli NF1 bacteria. The fusion protein was induced as described before (23) In order to increase the sensitivity of EBNA2A detection, the peroxidase-antiperoxidase (PAP) technique was used. After incubation with the primary antibody and washing in PBS-Tween, the filter was incubated for 1 h with swine anti-rabbit immunoglobulin serum (Dakopatts) diluted 1:100 in PBS-milk and then washed and incubated for 2 h with rabbit PAP (Dakopatts) diluted 1:400 in PBS-milk. The filter was washed and stained as described above. (Fig. 1A) . Transplanted NPC tumors hybridized only with the EBNA2A probe (Fig. 1A) and not with the EBNA2B probe (Fig. 1B) (Fig. 1A) . This EBNA2 polymorphism has already been detected in the M-ABA EBV genome (1). CR2 transcription analysis in transplanted NPC tumors. RNA extracted from the five NPC cell lines was probed with a 1.6-kb cDNA fragment subcloned from the CR2-coding clone A 4.11 (33) . No signal was detected by Northern blot analysis even after long exposure of the films. On the other hand, a specific 5-kb mRNA was expressed in Raji and not in HSB2 cells, a T-cell line not expressing CR2. A cDNA probe coding for the housekeeping protein GAPDH hybridized to a 1.4-kb mRNA in each lane of the filter (Fig. 2) .
RESULTS

Detection of EBV
To improve the sensitivity of our transcriptional assay, RNase mapping experiments were performed since this technique allows us to detect as little as 0.1 pg of specific RNA (20) . With an autoradiographic exposure of 3 days, the 450-bp CR2 band corresponding to the EcoRI-PvuII fragment subcloned from the cDNA p1.6 CR2 (33) was detected in BL36 and Raji cells, two EBV-positive Burkitt's lymphoma lines, and not in tRNA, a negative control (Fig. 3) . Different quantities of nonselected Raji cell RNA were tested in amounts ranging between 20 and 0.5 ,g to estimate the threshold of CR2 detection. The specific CR2 fragment was readily detected with 1 p.g or more of Raji RNA but not with 0.5 ,ug of RNA (Fig. 3) . A faint CR2 transcript was detectable at this level in C15 and C18 but not in C17. The intensity of the signal obtained with NPC RNA was weaker than that obtained with 1 ,ug of Raji RNA but similar to those obtained with BL70, an EBV-negative Burkitt's lymphoma line (Fig. 3) .
Blast2/CD23 transcription analysis. Northern blots were hybridized with the pFcERl insert, a full-length cDNA encoding the human low-affinity Fcc receptor (18) . Three NPC cell lines (C15, C17, and T1915) were found to transcribe the 1.7-kb mRNA (Fig. 4) . This transcript was also detected in Raji cells, a positive control, and not in HSB-2 Total RNA was annealed to the RNA probe, which contained the sequence corresponding to the 450-bp EcoRI-PvuII fragment of the p1.6 CR2 cDNA (33) , and then digested with RNases A and T1. The sizes of protected bands were analyzed by polyacrylamide gel electrophoresis and exposed 3 days in autoradiography. A 30-,ug amount of total RNA was analyzed in each lane, and different RNA quantities prepared from Raji cells were tested in a range between 20 and 0.5 ,ug (20, 10, 5, 2.5, 1, and 0.5 ,ug). All different dilutions of Raji RNA were completed up to 30 tg with tRNA. tRNA is a negative control. BL36 and Raji are two Burkitt's lymphoma lines associated with EBV and CR2 positive. BL70 is an EBV-negative Burkitt's lymphoma line. C15, C17, and C18 are EBV-associated NPC lines. Molecular size markers are pBR322 cut by MspI (sizes in base pairs). cells, a known Blast2/CD23-negative cell line. No major variations of transcription were detected during the passages of the NPC cell lines in nude mice. However, we found variations of Blast2/CD23 mRNA expression in C17 correlated with the duration of tumor growth in nude mice (data not shown). RNA extracted from different nonhematopoietic malignant cell lines, including sarcoma, carcinoma, and neurological tumors, did not hybridize with the pFceRl probe (Fig. 5) , whereas total RNA and polyadenylated [poly(A)+] RNA from C15 did. Blast2/CD23 mRNA cannot be expressed from contaminant murine tissues, since RNA extracted from nude mice tissue failed to hybridize with the pFcsRl probe.
Detection of soluble form of Blast2/CD23 protein in trans- (Fig. 6) . SCD23 was present in large quantities in the supernatant of BL2 cells converted with the B95/8 EBV strain, whereas no SCD23 was detected in HT29 cell (colonic carcinoma) supernatant conditioned and prepared under the same conditions (Fig. 6) . SCD23 was also detected in C17 supernatant, with quantitative variations comparable to those observed in the transcription study, and was undetectable in C18 supernatant (data not shown).
Analysis of EBNA2A and EBNA1 protein expression in transplanted NPC tumors. DNA Southern analysis revealed that the five NPC cell lines harbored an EBV with an EBNA2 gene of type A. We therefore investigated by immunoblotting to see whether our NPC cell lines expressed the EBNA2A protein and whether such expression was correlated with CD23 expression. The rabbit sera specific for the EBNA2A protein detected a molecule of ca. 80 kDa in the EBV-associated lymphoid lines JI, Raji, and BL60 (Fig.  7A) . As expected, EBNA2A was not detected in the EBVnegative Burkitt's lymphoma line BL41 nor in CEM, a malignant T-cell line. EBNA2A was not detected in any of the five transplanted NPC tumors tested (Fig. 7A) . To estimate the integrity and the quantity of the proteins loaded, the filters hybridized with an EBNA1 rabbit antiserum clearly detected the 70-kDa EBNA1 protein in the five NPC and all EBV-positive cell lines tested (Fig. 7B) . 
DISCUSSION
Our experiments establish that the EBV receptor CR2 is transcribed at very low levels in certain EBV-positive NPC lines. CR2 mRNA was not detectable by the usual Northern analysis, whereas by using the more sensitive RNase mapping assay (20) , two of the three NPC lines tested were found to transcribe the CR2 gene. The sizes of the protected bands corresponding to CR2 mRNA were found to be identical in EBV-associated lymphoid and in NPC lines. The intensity of the signal obtained with C15 and C18 was lower than that obtained with 1 ,ug of nonselected RNA prepared from the CR2-EBV-positive lymphoma line Raji and was equivalent to those of BL70, an EBV-negative Burkitt's lymphoma line. Transcriptional quantification showed that steady-state CR2 mRNA levels were approximately 50 times lower in C15 and C18 than in Raji. Therefore, it appears that levels of CR2 mRNA found in malignant EBV-associated NPC epithelial cells differ from those in EBV-positive B-cell lines, where CR2 mRNA is readily detectable (Calender et al., submitted for publication; M. Billaud, unpublished data).
It has been reported that frozen sections of basal or suprabasal layers of normal pharyngeal epithelium express a molecule which reacts with HB-5, B2, and AB-1, three anti-CR2 monoclonal antibodies (34, 36 This raises the possibility that the uterine cervix is a site for virus shedding (25) . However, clear-cut results have not been obtained for CR2 expression on NPC cells (13, 14) . It is noteworthy that single-cell suspensions as well as tumor imprints of C15, C17, and C18 were found to be CR2 negative when tested with OKB7 and HB-5, two monoclonal antibodies which recognize distinct epitopes of the CR2 molecule (4) . This discrepancy between the RNA and protein data is reminiscent of EBV conversion of EBV-negative lymphoma cells. EBV-negative lymphoma cell lines such as BL70, which we tested in this study, express very low levels of CR2 molecules but are nevertheless infectable by EBV (6) . Since CR2 transcription was found to be similar in C15 and C18 to that in BL70, we assume that, as in the conversion model mentioned above, subdetectable levels of CR2 proteins are expressed by NPC cells. Further experiments will establish whether such low CR2 expression could permit EBV infection of malignant epithelial nasopharyngeal cells.
Upon EBV infection in vitro, human B lymphocytes are transformed to a state of continuous proliferation through the activation of a B-cell proliferation pathway, involving the up expression of the molecule Blast2/CD23 (29, 30) . Blast2/ CD23 is a leukocyte differentiation antigen which is the same molecule as the low-affinity receptor for the Fc portion of human immunoglobulin E (2, 37). Blast2/CD23 is postulated to play an important role in EBV-induced B-cell immortalization, since its shed form possesses B-cell growth factor activity (28) , which could be involved in the autocrine loop activated by the virus (15) . Although Blast2/CD23 was not detected on the surface of NPC cells by the usual immunofluorescence staining techniques, we cannot exclude the possibility that Blast2/CD23 was released directly into the supernatant of short-term cultures of NPC tumors. We now report that these malignant epithelial cells express the 1.7-kb Blast2 mRNA and that the soluble form of Blast2/CD23 protein is detectable in NPC tumor supernatants. Expression was not found in the other nonhematopoietic cancers tested. Blast2/CD23 expression was also not detected in CNE-1 and CNE-2 (Rousselet et al., submitted for publication), two malignant epithelial cell lines established from differentiated NPC biopsies (38) which lack the EBV genome, suggesting that EBV infection may be critical in Blast2/CD23 induction. EBNA2 is a candidate in this transactivation process, since its expression turns on Blast2/CD23 expression in lymphoid cells (6, 31 ; Cordier et al., submitted). In contrast to the lymphoid system, the expression of Blast2/CD23 in NPC cells was not correlated with the expression of this viral protein. This suggests that if Blast2/CD23 expression depends on EBV, it might be mediated through EBV proteins other than EBNA2. Indeed, the pattern of EBV gene expression in NPC cells was reported to be different from that of lymphoid cells with down expression of EBNA2, -3, and -5 but frequent expression of latent membrane protein (LMP) and constant expression of EBNA1 (10, 35) . Recently, the introduction of LMP by gene transfer into a human EBVnegative Burkitt's lymphoma line was demonstrated to increase the expression of Blast2/CD23 (32) . The 62-kDa LMP protein was clearly identified in C15, weakly identified in C17, and barely detectable in C18 and T1530, but the LMP status of T1915 has not been resolved (P. Busson and M. Billaud, manuscript in preparation). Therefore, Blast2/CD23 activation in NPC cells could be mediated through LMP expression. However, it remains to be explained why C18 and T1530, which seem to express low levels of LMP, do not express Blast2/CD23. Alternatively, one can postulate that the NPC progenitor cells have an epithelial differentiation pattern which involves Blast2/CD23 expression. Regarding this hypothesis, one should note that Blast2/CD23, postu-lated to be a specific leukocyte marker, has recently been shown to be expressed at high levels on follicular dendritic cells (17) . Consequently, with regard to the difficulty of detecting Blast2/CD23 by immunofluorescence on NPC cell membranes despite observed expression, either an alternative splicing removes the transmembrane coding exon of CD23 mRNA or destabilization of the membrane form of Blast2/CD23 protein involves rapid cleavage and shedding of the soluble moiety. Finally, we and others have demonstrated that in NPC cells, as in the lymphoid system, interleukin-4 induces Blast2/CD23 expression, and induction is blocked by interferon gamma (Rousselet et al., submitted) .
Since C18 and T1530 do not express Blast2/CD23 protein, different NPC cell lines exist. In addition, Blast2/CD23 has been reported to be spatially associated with human leukocyte antigen (HLA) DR on cell surfaces (3), and C1S and C17 consistently coexpress both HLA DR and Blast2/CD23, whereas C18 does not (4) . C1S and C17 also express CDW40
antigen and soluble factors with interleukin-1 activity, whereas C18 cells do not express these molecules (4).
Transplanted NPC tumors also provide a means of investigating whether soluble Blast2/CD23 is able to act synergystically with other growth factors, such as molecules with interleukin-1 activity which may be present in the supernatant of NPC cultures (5) , to promote growth of these epithelial cells.
